Migraine Sufferers Are Racing To Get New Drug After FDA Approval, But Insurers Might Stand In Way
A new therapy has given hope to desperate migraine sufferers, but some insurers are balking at the price.
San Francisco Chronicle:
Migraine Patients’ Coverage Headache: FDA OK Doesn’t Mean Insurance Will Pay
Patients are learning a hard lesson in drug development: Just because the FDA says something is ready for wide release doesn’t mean it’s cost-effective from an insurer’s point of view. And if it’s not considered cost-effective, the insurer won’t pay for it — which is what is happening with Aimovig and the other new drugs. (Allday, 11/25)